|1.||Carlsson, Bo: 3 articles (11/2006 - 01/2002)|
|2.||Faergemann, Jan: 3 articles (11/2006 - 01/2002)|
|3.||Lavin, Thomas: 2 articles (11/2006 - 01/2002)|
|4.||Yazdanparast, Parviz: 2 articles (11/2006 - 03/2006)|
|5.||Sun, Xing-Ying: 2 articles (03/2006 - 01/2002)|
|6.||Zhao, Xiao-He: 2 articles (03/2006 - 01/2002)|
|7.||Pisarev, M A: 2 articles (05/2004 - 11/2003)|
|8.||Covelli, Danila: 1 article (10/2014)|
|9.||Stagi, Stefano: 1 article (10/2014)|
|10.||Cirello, Valentina: 1 article (10/2014)|
10/01/2012 - "TRIAC was effective and safe in ameliorating the effects of hyperthyroidism and ADHD symptoms in a child with known genetic RTH. "
10/01/1997 - "We thus recommend testing the efficacy of TRIAC therapy in all RTH patients presenting with clinical features of hyperthyroidism."
06/01/2002 - "Such was the case with this patient who presented with signs, symptoms, and biochemical evidence of hyperthyroidism that promptly resolved after discontinuation of tiratricol therapy. "
06/01/2002 - "Symptomatic hyperthyroidism in a patient taking the dietary supplement tiratricol."
11/01/1989 - "3,5,3'-triiodothyroacetic acid is an effective inhibitor of TSH secretion in central hyperthyroidism. "
10/01/1992 - "We found no significant clinical improvement with a maximal dose of Triac (2.1 mg/day), only minimal reduction in goiter size; mild decreases in T3 (9.9 to 6.7 nmol/L), free T4 (205 to 113 pmol/L), and TSH (5.7 to 5.4 mU/L); no change in STI (left ventricular ejection time, 0.389 to 0.401 sec); and an increase in O2 consumption (VO2, 164 to 209 mL/min). "
11/01/2007 - "These results show that Triac is more effective than L-T4 on goiter size, while having similar peripheral effects."
11/01/2003 - "The present results show that TRIAC is more effective than L-T(4) in the reduction of goiter size, with comparable effects on peripheral parameters."
11/01/2007 - "Goiter volume fell by at least 50% in 42% of patients treated with Triac and in 17.7% of patients treated with L-T4 (p=0.15). "
05/01/2004 - "Our results showed that TRIAC was more effective than T (3) to reduce MMI-induced goiter in a short-term goiter involution assay. "
|3.||Thyroid Hormone Resistance Syndrome (Thyroid Hormone Resistance)
08/01/1989 - "Triac has been used successfully to treat eight patients with thyroid hormone resistance. "
08/01/1989 - "3,5,3'-triiodothyroacetic acid therapy for thyroid hormone resistance."
10/01/2012 - "Long-term 3,5,3'-triiodothyroacetic acid therapy in a child with hyperthyroidism caused by thyroid hormone resistance: pharmacological study and therapeutic recommendations."
01/01/2013 - "We present another case of an association of thyroid hormone resistance syndrome and papillary thyroid carcinoma, and we share our experience with 3,5,3'-triiodothyroacetic acid, which made possible an easier management of the carcinoma after surgery, maintaining the TSH levels suppressed despite the resistance to thyroid hormones."
10/01/2012 - "The effectiveness of short-term 3,5,3'-triiodothyroacetic acid (TRIAC) therapy for the treatment of hyperthyroidism caused by thyroid hormone resistance (RTH) has been documented. "
|4.||Body Weight (Weight, Body)
02/01/1988 - "The body weight significantly fell in both groups, without any difference between TRIAC treated and untreated patients. "
01/01/1982 - "Treatment by TRIAC decreases the body weight gain in obese rats compared with controls but it has no statistically significant effect on the relative protein turnover in either obese or lean rats."
01/01/1982 - "Genetically obese female rats (fa/fa) and their lean littermates (Fa/-) were given oral administration of 3,5,3-triiodothyroacetic acid (TRIAC) (20 micrograms/ 100 g of body weight/ day) during 4 weeks. "
03/01/1989 - "When 30 micrograms triac/100 g body weight was administered, serum TSH levels remained depressed 24 h later, while pituitary mRNA content was essentially the same as in the hypothyroid controls. "
05/15/1986 - "Comparative effects of 3,5-dimethyl-3'-isopropyl-L-thyronine (DIMIT) and 3,5-diiodo-3'-isopropylthyroacetic acid (IpTA2) on body weight gain and lipid metabolism in genetically obese Zucker rats."
11/01/2006 - "This study indicates that topical treatment with TRIAC appears to reverse glucocorticoid-induced skin atrophy under the narrow conditions tested."
11/01/2006 - "The present study concerns the effect of topical treatment with a cream formulation of triiodothyroacetic acid (TRIAC) in comparison with a placebo preparation in producing a reversal of skin atrophy induced by long-term employment of topical glucocorticoid therapy in humans. "
03/01/2006 - "This study indicates that TRIAC may have a therapeutic effect on BM-induced dermal atrophy in mouse skin and a direct stimulatory effect on dermal proliferation when given alone."
03/01/2006 - "The addition of TRIAC to 0.05% BD cream in a final concentration of 0.1% was able partially to reverse the dermal atrophy by 15% (p < 0.05). "
03/01/2006 - "A combination of 0.2 mM BM and 10 nmol/cm(2) TRIAC was able to prevent dermal atrophy by 18%. "
|1.||3,3',5-triiodothyroacetic acid (Triac)
|4.||Thyrotropin (Thyroid-Stimulating Hormone)
|9.||Thyrotropin-Releasing Hormone (Protirelin)
|2.||Orthotic Devices (Orthosis)